DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kobayashi, K.
Right arrow Articles by Chiba, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kobayashi, K.
Right arrow Articles by Chiba, K.

Vol. 27, Issue 7, 763-766, July 1999

SHORT COMMUNICATION
Sertraline N-Demethylation Is Catalyzed by Multiple Isoforms of Human Cytochrome P-450 In Vitro

Kaoru Kobayashi, Tomoko Ishizuka, Noriaki Shimada, Yoshitaka Yoshimura, Kunitoshi Kamijima, and Kan Chiba

Laboratory of Biochemical
Pharmacology and Toxicology
Faculty of Pharmaceutical Sciences
Chiba University,
Chiba, Japan (K.K., T.I., K.C.)
Materials Technology Research Laboratories
Daiichi Pure Chemicals Co. Ltd.
Ibaraki (N.S.), Japan
Department of Psychiatry
School of Medicine
Showa University
Tokyo, Japan (Y.Y., K.K.)

Sertraline, a new antidepressant of the selective serotonin reuptake inhibitor class, is extensively metabolized to desmethylsertraline in humans. We identified the cytochrome P-450 (CYP) isoforms involved in sertraline N-demethylation using pooled human liver microsomes and cDNA-expressed CYP isoforms. Eadie-Hofstee plots for the sertraline N-demethylation in human liver microsomes were monophasic. The estimated Michaelis-Menten kinetic parameters were: KM = 18.1 ± 2.0 µM, Vmax = 0.45 ± 0.03 nmol/min/mg of protein, and Vmax/KM = 25.2 ± 4.3 µl/min/mg of protein. At the substrate concentration of 20 µM, which approximated the apparent KM value, sulfaphenazole (CYP2C9 inhibitor) and triazolam (CYP3A substrate) reduced the N-demethylation activities by 20 to 35% in human liver microsomes, whereas the inhibition induced by mephenytoin (CYP2C19 substrate) or quinidine (CYP2D6 inhibitor) was marginal. The anti-CYP2B6 antibody inhibited the sertraline N-demethylation activities by 35%. Sertraline N-demethylation activities were detected in all cDNA-expressed CYP isoforms studied. In particular, CYP2C19, CYP2B6, CYP2C9-Arg, CYP2D6-Val, and CYP3A4 all showed relatively high activity. When the contributions of CYP2D6, CYP2C9, CYP2B6, CYP2C19, and CYP3A4 were estimated from the Vmax/KM of cDNA-expressed CYP isoforms and from their contents in pooled human liver microsomes, the values were found to be 35, 29, 14, 13, and 9%, respectively. The results suggest that at least five isoforms of CYP (CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4) are involved in the sertraline N-demethylation in human liver microsomes and that the contribution of any individual isoform does not exceed 40% of overall metabolism. Therefore, concurrent administration of a drug that inhibits a specific CYP isoform is unlikely to cause a marked increase in the plasma concentration of sertraline.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
R. L. Walsky and R. S. Obach
A Comparison of 2-Phenyl-2-(1-piperidinyl)propane (PPP), 1,1',1''-Phosphinothioylidynetrisaziridine (ThioTEPA), Clopidogrel, and Ticlopidine as Selective Inactivators of Human Cytochrome P450 2B6
Drug Metab. Dispos., November 1, 2007; 35(11): 2053 - 2059.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
Y. M. Kim, S. H. Yoo, R. Y. Kang, M. J. Kim, Y. Y. Bae, Y. K. Lee, S. J. Jeon, K. J. Chon, S. M. Shin, S. G. Kim, et al.
Identifying drugs needing pharmacogenetic monitoring in a Korean hospital
Am. J. Health Syst. Pharm., January 15, 2007; 64(2): 166 - 175.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. P. Gibbs, R. Hyland, and K. Youdim
Minimizing Polymorphic Metabolism in Drug Discovery: Evaluation of the Utility of in Vitro Methods for Predicting Pharmacokinetic Consequences Associated with CYP2D6 Metabolism
Drug Metab. Dispos., September 1, 2006; 34(9): 1516 - 1522.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
S. J. Gardiner and E. J. Begg
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
C. L. Devane, Z. N. Stowe, J. L. Donovan, D. J. Newport, P. B. Pennell, J. C. Ritchie, M. J. Owens, and J.-S. Wang
Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities.
J Psychopharmacol, July 1, 2006; 20(4 Suppl): 54 - 59.
[Abstract] [PDF]

Home page
 PsychosomaticsHome page
N. B. Sandson, S. C. Armstrong, and K. L. Cozza
An Overview of Psychotropic Drug-Drug Interactions
Psychosomatics, October 1, 2005; 46(5): 464 - 494.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. S. Obach, L. M. Cox, and L. M. Tremaine
SERTRALINE IS METABOLIZED BY MULTIPLE CYTOCHROME P450 ENZYMES, MONOAMINE OXIDASES, AND GLUCURONYL TRANSFERASES IN HUMAN: AN IN VITRO STUDY
Drug Metab. Dispos., February 1, 2005; 33(2): 262 - 270.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E. Stormer, L. L. von Moltke, R. I. Shader, and D. J. Greenblatt
Metabolism of the Antidepressant Mirtazapine In Vitro: Contribution of Cytochromes P-450 1A2, 2D6, and 3A4
Drug Metab. Dispos., October 1, 2000; 28(10): 1168 - 1175.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.